Additional data from Affibody’s HER2 radiopharmaceutical program presented at PepTalk
News
January 15, 2025
Affibody AB (“Affibody”) announces presentation of data from IND enabling preclinical studies with the radiotherapeutic agent 177Lu-ABY-271 for treatment of HER2 expressing metastatic disease. The data will be presented today at the annual PepTalk conference.
The data will be presented in the Targeted Radioligand Therapies session at the 24th annual PepTalk conference on January 15, 2025.
“The data at hand suggest that our drug candidate could reach meaningful levels of drug in tumors of patients with HER mediated disease” says Fredrik Frejd, CSO, Affibody AB. “We have recently filed a clinical trial application and anticipate early clinical data by mid year”, he continues.
The presentation details are as follows:
Title: Expanding Targeted Radioligand Therapy to HER2-Expressing Breast Cancer Using Affibody Molecules as Targeting Vectors.
Presenter: Prof. Fredrik Frejd, CSO Affibody.
Session: Targeted Radioligand Therapies.
Time and date: January 15, 2025, 08:20 am PST.
Additional information is available at: https://www.chi-peptalk.com/targeted-radioligand-therapies#2